Paricalcitol is FDA-approved for which of the following condition(s):: (A) Rickets, (B) Osteomalacia, (C) Primary hyperparathyroidism, (D) Secondary hyperparathyroidism
Answer is D. Paricalcitol: It is a synthetic calcitriol derivative Reduces serum PTH levels without producing hypercalcemia or altering serum phosphorus Administered orally or intravenously FDA-approved for treating secondary hyperparathyroidism in patients with CKD